IP Library Granted Patent US 12,324,913
Granted Patent B2
US 12,324,913 · App. 17/235,649 · Granted Jun 10, 2025

Method and device for treating microscopic residual tumors remaining in tissues following surgical resection

Inventors: Paul Goldfarb (San Diego, CA); Dietmar Rabussay (Solana Beach, CA)
Assignee: Grand Decade Developments Limited
A61N1/327A61K9/0009A61K38/14A61M5/19A61M5/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,913
App. No.
17/235,649
Granted
Jun 10, 2025
Kind
B2
Abstract

This invention concerns treating apparently normal tissue surrounding sites of cancerous tumors so as to reduce both the probability of a recurrence of cancer at and near the site of a cancerous tissue, and to reduce the amount of apparently healthy tissue that is usually excised along with the tumor, thereby providing a substantial benefit to the cancer patient by eliminating or delaying tumor recurrence and sparing normal tissue for its functionality and for avoiding unnecessary disfigurement.

Claims (40)

1. A method of reducing recurrence of tumor cell growth in a mammalian tissue, the method comprising:

(a) resecting a tumor;

(b) administering an agent capable of reducing tumor cell growth to a margin tissue after resecting the tumor; and

(c) applying at least one electroporative electric pulse to the margin tissue after resecting the tumor, thereby delivering the agent into cells of the margin tissue;

wherein recurrence of tumor cell growth in the mammalian tissue is reduced,

wherein the electroporative electric pulse is administered using an electroporation device comprising:

an array of a multiplicity of electrodes capable of channeling a fluid volume from at least one variable volume reservoir to the margin tissue around the tumor when the multiplicity of electrodes are positioned in the margin tissue around the tumor,

wherein said multiplicity of electrodes can be further energized in a predetermined format selected from the group consisting of energizing single pairs of electrodes, energizing opposed pairs of electrodes, energizing a selected portion of said electrodes sequentially, and energizing a selected portion of said electrodes simultaneously,

wherein the electroporation device further comprises:

the array of said multiplicity of electrodes comprising lumens running therethrough for transporting a fluid medium;

an array of compartments capable of containing a fluid medium and in fluid communication with said lumens;

an array of plungers corresponding to said array of compartments wherein a plunger is fit into each compartment of said array of compartments and wherein said plungers are capable of slidably adjustable positioning in their respective compartments;

an actuator for slidably adjusting positioning of said plungers, wherein the actuator is an electric motor; and

a source of electrical energy connectable to said multiplicity of electrodes for imparting to said multiplicity of electrodes the electroporative electric pulse.

2. The method of claim 1 , wherein the agent is selected from the group consisting of a chemotherapeutic drug, bleomycin, cisplatin, a polypeptide, an antibody, an RNAi, an antisense nucleic acid, an expressible gene encoding a therapeutically active polypeptide, a chemokine, and a cytokine.

3. The method of claim 1 , wherein administering the agent to the margin tissue comprises intravenous administration.

4. The method of claim 1 , wherein a tumor cell in the mammalian tissue is selected from the group consisting of: a cancer cell in cutaneous tissue, a cancer cell located on a head or neck of a mammal, a squamous cell carcinoma, a colon carcinoma, and a melanoma cell.

5. The method of claim 1 , wherein the electroporative electric pulse comprises a pulse having a nominal field strength selected from the group consisting of: between 800 and 1500 V/cm, between 600 and 1500 V/cm, between 600 and 1400 V/cm, between 200 and 800 V/cm, between 1 and 600 V/cm, between 200 to 600 V/cm, between 400 and 600 V/cm, 1200 V/cm, and 1500 V/cm.

6. The method of claim 1 , further comprising administering one or more additional cancer therapies.

7. The method of claim 6 , wherein the one or more additional cancer therapies is selected from the group consisting of: radiation, chemotherapy, and antibody therapy.

8. The method of claim 1 , wherein the method comprises reducing microtumor seeding in the margin tissue.

9. The method of claim 1 , wherein resecting the tumor comprises partially removing the tumor.

10. The method of claim 1 , wherein resecting the tumor comprises removing a primary tumor mass.

11. A method of reducing recurrence of tumor cell growth in a mammalian tissue, the method comprising:

(a) administering an agent capable of reducing tumor cell growth to a tumor and a margin tissue;

(b) applying at least one electroporative electric pulse to the tumor and the margin tissue, thereby delivering the agent into cells of the tumor and the margin tissue; and

(c) resecting the tumor after applying at least one electroporative electric pulse to the tumor and the margin tissue;

wherein recurrence of tumor cell growth in the mammalian tissue is reduced,

wherein the electroporative electric pulse is administered using an electroporation device comprising:

an array of a multiplicity of electrodes capable of channeling a fluid volume from at least one variable volume reservoir to the margin tissue around the tumor when the multiplicity of electrodes are positioned in the margin tissue around the tumor,

wherein said multiplicity of electrodes can be further energized in a predetermined format selected from the group consisting of energizing single pairs of electrodes, energizing opposed pairs of electrodes, energizing a selected portion of said electrodes sequentially, and energizing a selected portion of said electrodes simultaneously,

wherein the electroporation device further comprises:

the array of said multiplicity of electrodes comprising lumens running therethrough for transporting a fluid medium;

an array of compartments capable of containing a fluid medium and in fluid communication with said lumens;

an array of plungers corresponding to said array of compartments wherein a plunger is fit into each compartment of said array of compartments and wherein said plungers are capable of slidably adjustable positioning in their respective compartments;

an actuator for slidably adjusting positioning of said plungers, wherein the actuator is an electric motor; and

a source of electrical energy connectable to said multiplicity of electrodes for imparting to said multiplicity of electrodes the electroporative electric pulse.

12. The method of claim 11 , wherein the agent is selected from the group consisting of a chemotherapeutic drug, bleomycin, cisplatin, a polypeptide, an antibody, an RNAi, an antisense nucleic acid, an expressible gene encoding a therapeutically active polypeptide, a chemokine, and a cytokine.

13. The method of claim 11 , wherein administering the agent to the tumor and the margin tissue comprises injecting the agent into the tumor and the margin tissue.

14. The method of claim 11 , wherein a tumor cell in the mammalian tissue is selected from the group consisting of: a cancer cell in cutaneous tissue, a cancer cell located on a head or a neck of a mammal, a squamous cell carcinoma, a colon carcinoma, and a melanoma cell.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2024
From: ONCOSEC MEDICAL INCORPORATED
To: GRAND DECADE DEVELOPMENTS LIMITED
Reel/Frame 067000/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: GOLDFARB, PAUL; RABUSSAY, DIETMAR
To: GENETRONICS, INC.
Reel/Frame 056034/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: INOVIO PHARMACEUTICALS, INC.
To: ONCOSEC MEDICAL INCORPORATED
Reel/Frame 056034/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: GENETRONICS, INC.
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 056034/0329 →
Continuity (5)
Continuation 15488288 · Apr 14, 2017
Continuation 13278721 · Oct 21, 2011
Division 11713181 · Mar 2, 2007
Provisional Application 60778740 · Mar 3, 2006
Related Publication 20210308451A1 · Oct 7, 2021
References Cited (46)
US 5993434A · Dev et al. · 1999 [cited by applicant]
US 6014584A · Hofmann et al. · 2000 [cited by applicant]
US 6528315B2 · Bureau et al. · 2003 [cited by applicant]
US 6763264B2 · Hofmann · 2004 [cited by examiner]
US 7109179B2 · Roth et al. · 2006 [cited by applicant]
US 7157079B2 · Nielsen et al. · 2007 [cited by applicant]
US 7537590B2 · Santini et al. · 2009 [cited by applicant]
US 7769440B2 · Hoff et al. · 2010 [cited by applicant]
US 8209006B2 · Smith et al. · 2012 [cited by applicant]
US 9037230B2 · Goldfarb et al. · 2015 [cited by applicant]
US 20020119519A1 · Ebner · 2002 [cited by examiner]
US 20030109478A1 · Fewel et al. · 2003 [cited by applicant]
US 20040009895A1 · Varadhachary · 2004 [cited by examiner]
US 20040014645A1 · Draghia-Akli et al. · 2004 [cited by applicant]
US 20050054594A1 · Zhang et al. · 2005 [cited by applicant]
US 20050054969A1 · Hoff et al. · 2005 [cited by applicant]
US 20050063058A1 · Langley · 2005 [cited by examiner]
US 20060024358A1 · Santini et al. · 2006 [cited by applicant]
US 20070088345A1 · Larson et al. · 2007 [cited by applicant]
US 20080075718A1 · Colson et al. · 2008 [cited by applicant]
US 20080091135A1 · Draghia-Akli et al. · 2008 [cited by applicant]
EP 1142606A2 · 2001 [cited by applicant]
JP 2000503586A · 2000 [cited by applicant]
JP 2003525912A · 2003 [cited by applicant]
JP 2005087519A · 2005 [cited by applicant]
JP 2005518904A · 2005 [cited by applicant]
WO WO199906101A1 · 1999 [cited by applicant]
WO WO199937538 · 1999 [cited by applicant]
WO WO2003075978A2 · 2003 [cited by applicant]
Burian et al., “Electroporation therapy in head and neck cancer”, Acta Otolaryngol (2003) 123:264-268. [cited by applicant]
EPO Communication pursuant to Article 94(3) EPC for EP Patent Application No. 07 751 8652 mailed Jun. 28, 2017. [cited by applicant]
European Search Report for European Patent Application No. 07751865.2, mailed Dec. 20, 2011. [cited by applicant]
Hanna et al., “Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site” Cancer Gene Therapy (2001) 8:151-157. [cited by applicant]
Heller et al., “Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin,” Cancer. Jul. 1, 1998;83(1):148-57. [cited by applicant]
Javorovic et al., “RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory aytotoxic T lymphocytes: a quantitative analysis” Molecular Therapy (2005) 12(4):734-743. [cited by applicant]
JPO Office Action for Japanese Patent Application No. 2008-557341, mailed Jan. 31, 2012. [cited by applicant]
Kashida et al., “In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice” Gene Therapy (2001) 8(16):1234-1240. [cited by applicant]
Li et al., “Regression of tumours by IFN-a electroporation gene therapy and analysis of the responsible genes by cDNA array”, Gene Therapy (2002) 9:390-397. [cited by applicant]
Li et al., “Regression of tumour growth and induction of long-term antitumour memory by Interleukin 12 electro-gene therapy” CancerSpectrum Knowledge Environment—J. of the National Cancer Institute (2002) 94(10):762-768. [cited by applicant]
Matsubara et al., “Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells,” Int J Oncol. Apr. 2001;18(4):825-9. [cited by applicant]
Sersa et al., “Electrochemotherapy with Cisplatin: potentiation of local Cisplatin antitumour effectiveness by application Df electric pulses in cancer patients” European J. of Cancer (1998) 34(8):1213-1218. [cited by applicant]
Shimizu et al., “Electrochemotherapy for digital chondrosarcoma,” J Orthop Sci. 2003;8(2):248-51. [cited by applicant]
Snoj, M., et al. “Successful Sphincter-Saving Treatment of an Anorectal Malignant Melanoma with Electrochemotherapy, Local Excision and Adjuvant Brachytherapy,” Anticancer Drugs. Mar. 2005;16(3):345-8. [cited by applicant]
Spugnini et al., “Rational design of new electrodes for electrochemotherapy,” J Exp Clin Cancer Res. Jun. 2005;24(2):245-54. [cited by applicant]
Spugnini et al., “Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model,” Cancer Chemother Pharmacol. Feb. 2007;59(3):375-81. Epub … [cited by applicant]
Tamura et al., “Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer” Human Gene Therapy (2001) 12(10):1265-1276. [cited by applicant]